Related Experiment Videos
Increased breakthrough bleeding during prophylaxis with B-domain deleted factor VIII--a robust meta-analytic finding.
R A Gruppo1, D Brown, M M Wilkes
1Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA. ralph.gruppo@cchmc.org
Haemophilia : the Official Journal of the World Federation of Hemophilia
|September 11, 2004
Summary
Full-length factor VIII (FL-FVIII) prophylaxis shows lower bleeding incidence than B-domain deleted recombinant factor VIII (BDD-rFVIII). This finding holds true regardless of patient age, supporting FL-FVIII for hemophilia treatment.
Area of Science:
- Hematology
- Clinical Pharmacology
- Evidence-Based Medicine
Background:
- Meta-analyses of observational studies are crucial for evidence-based clinical decisions.
- Factor VIII (FVIII) concentrates are used for hemophilia prophylaxis.
- Comparing full-length FVIII (FL-FVIII) and B-domain deleted recombinant FVIII (BDD-rFVIII) efficacy is important.
Purpose of the Study:
- To compare the clinical efficacy of FL-FVIII versus BDD-rFVIII in patients undergoing prophylaxis.
- To investigate differences in breakthrough bleeding incidence between the two FVIII concentrate types.
Main Methods:
- A random effects model was used to analyze available clinical studies.
- Data from studies reporting median bleeds were converted to mean annual total bleeds.
- Sensitivity analyses were performed using a range of conversion factors (1.4-2.6).
- The impact of patient age on the multivariate model was examined.
Main Results:
- Bleeding incidence was statistically higher in patients treated with BDD-rFVIII compared to FL-FVIII.
- This difference remained significant even with the lowest conversion factor (1.4).
- Exposure to BDD-rFVIII was an independent predictor of bleeding, irrespective of patient age.
Conclusions:
- FL-FVIII prophylaxis is associated with a lower incidence of breakthrough bleeding compared to BDD-rFVIII.
- The findings are robust and consistent across different patient age groups.
- This meta-analysis supports the use of FL-FVIII for improved prophylactic outcomes in hemophilia patients.